Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Novo Nordisk faces shareholder lawsuits alleging the company made misleading statements about the tolerability of CagriSema, its next-generation weight-loss drug. Clinical trial results for CagriSema released in 2025 fell short of investor expectations, leading to a significant decline in the company's market value. Shareholders contend the company did not adequately disclose tolerability concerns before the trial data became public. Novo Nordisk has not issued a public response to the litigation.

Next story